lanraplenib   Click here for help

GtoPdb Ligand ID: 9764

Synonyms: compound 39 [PMID: 32292557] | Ex.-2, US9290505 | example 2 [US9290505] | GS-9876 | GS9876
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Lanraplenib (GS-9876) was claimed as a Syk tyrosine kinase inhibitor in Gilead Sciences' patent US9290505 [2]. Formal name>structure was disclosed in 2020 [1]. Lanraplenib is in development for autoimmune diseases including SLE and Sjögren's syndrome.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 109.73
Molecular weight 443.22
XLogP 1.9
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Nc1cncc(n1)c1cn2ccnc2c(n1)Nc1ccc(cc1)N1CCN(CC1)C1COC1
Isomeric SMILES Nc1cncc(n1)c1cn2ccnc2c(n1)Nc1ccc(cc1)N1CCN(CC1)C1COC1
InChI InChI=1S/C23H25N9O/c24-21-12-25-11-19(28-21)20-13-32-6-5-26-23(32)22(29-20)27-16-1-3-17(4-2-16)30-7-9-31(10-8-30)18-14-33-15-18/h1-6,11-13,18H,7-10,14-15H2,(H2,24,28)(H,27,29)
InChI Key XCIGZBVOUQVIPI-UHFFFAOYSA-N
Immunopharmacology Comments
Lanraplenib (GS-9876) was developed for potential to treat autoimmune and inflammatory diseases [2]. It is selective for SYK which is a kinase in the signalling pathways downstream of the B cell receptor and other cell surface receptors including CD74, Fc receptors, and integrins.